Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load
verfasst von:
Phionah Kibalama Ssemambo, Mary Gorrethy Nalubega-Mboowa, Arthur Owora, Robert Serunjogi, Susan Kironde, Sarah Nakabuye, Francis Ssozi, Maria Nannyonga, Philippa Musoke, Linda Barlow-Mosha
Many HIV-infected African children gained access to antiretroviral treatment (ART) through expansion of PEPFAR programs since 2004 and introduction of “Test and Treat” WHO guidelines in 2015. As ART access increases and children transition from adolescence to adulthood, treatment failure is inevitable. Viral load (VL) monitoring in Uganda was introduced in 2016 replacing clinical monitoring. However, there’s limited data on the comparative effectiveness of these two strategies among HIV-infected children in resource-limited settings (RLS).
Methods
HIV-infected Ugandan children aged 1–12 years from HIV-care programs with > 1 year of first-line ART using only immunologic and clinical criteria to monitor response to treatment were screened in 2010. Eligible children were stratified by VL ≤ 400 and > 400 copies/ml randomized to clinical and immunological (control) versus clinical, immunological and VL monitoring to determine treatment failure with follow-up at 12, 24, 36, and 48 weeks. Plasma VL was analyzed retrospectively for controls. Mixed-effects logistic regression models were used to compare the prevalence of viral suppression between study arms and identify factors associated with viral suppression.
Results
At baseline all children (n = 142) were on NNRTI based ART (75% Nevirapine, 25% efavirenz). One third of ART-experienced children had detectable VL at baseline despite high CD4%. Median age was 6 years (interquartile range [IQR]: 5–9) and 43% were female. Overall, the odds of viral suppression were not different between study arms: (arm by week interaction, p = 0.63), adjusted odds ratio [aOR]: 1.07; 95%CI: 0.53, 2.17, p = 0.57) and did not change over time (aOR: 0 vs 24 week: 1.15; 95% CI: 0.91, 1.46, p = 0.24 and 0 vs 48 weeks: 1.26; 95%CI: 0.92, 1.74, p = 0.15). Longer duration of a child’s ART exposure was associated with lower odds of viral suppression (aOR: 0.61; 95% CI: 0.42, 0.87, p < .01). Only 13% (9/71) of children with virologic failure were switched to second-line ART, in spite of access to real-time VL.
Conclusion
With increasing ART exposure, viral load monitoring is critical for early detection of treatment failure in RLS. Clinicians need to make timely informed decisions to switch failing children to second-line ART.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ART
Antiretroviral treatment
VL
Viral load
IQR
Interquartile range
aOR
Adjusted odds ratio
RLS
Resource limited settings
Background
The 2017 UNAIDS report estimated that 2.1 million children under the age of 15 years were living with HIV, with the majority of these living in Sub-Saharan Africa. Currently in Uganda, an estimated 47% of children living with HIV are receiving antiretroviral therapy (ART) [1]. Although ART became available about a decade ago, accessibility and coverage among treatment-eligible children and adolescents in resource-limited settings is lower than adults with 60% of eligible children receiving ART compared to 84% adults [2‐6]. Efforts made towards stepping up access to first-line ART have led to positive immunological and virologic outcomes with more children maintained on ART for a longer period of time into adolescence and adulthood [7‐9]. However, prolonged use of ART predisposes these children to treatment failure over time [10‐13].
Monitoring response to therapy in HIV-infected children has previously been done using CD4 cell counts (immunologic) and clinical criteria because of limited access, lack of technical expertise, inadequate laboratory infrastructure and the high costs associated with viral load testing. This was linked to missed opportunities for timely identification of virologic failure and switch to second-line ART among candidate children (i.e. those who may have benefited from second-line ARV therapy), therefore paving way for emergence of drug resistance [14‐17]. In Uganda, the use of immunologic criteria to determine when to switch to second-line ART had low sensitivity (13%) as a marker of viral suppression [18, 19]. Currently, WHO recommends virologic monitoring as the gold standard for diagnosing treatment failure [20, 21]. This is in anticipation of more children with poor response to ART being identified on time and given the appropriate management to improve overall survival and quality of life. In 2016, Uganda began implementing viral load testing for all pediatric patients on ART twice a year [22, 23].
Anzeige
Although there have been some studies done in low income countries that have highlighted the importance of measuring viral load as a more robust method of monitoring response to ART in resource limited settings [24‐28], little evidence exists for the effectiveness of such a practice among treatment experienced children previously monitored without viral loads (VL), in resource limited settings. Unlike recent ART initiators, treatment-experienced children may have been maintained on a failing regimen for a considerable amount of time without documentation of virologic failure (based on clinical and immunologic information). Therefore, the objectives of this study were to (1) compare the prevalence of viral suppression and associated predictors between ART treatment-experienced children randomized to either clinical and immunological (control arm) or clinical, immunological plus VL monitoring (intervention arm) and (2) compare prevalence and correlates of decisions to switch to second-line ART between the two study arms at 12, 24, 36, and 48 weeks of follow-up.
Methods
Study design
We conducted a two-center, parallel-group randomized clinical trial study in Kampala, Uganda. The study adhered to CONSORT guidelines. HIV-infected children between the ages 1 and 12 years on ART were randomly assigned using a computer-generated list of random numbers (by the study statistician). Randomization was implemented in blocks (size = 4) stratified based on baseline VL (≤ 400 and > 400 HIV RNA copies/ml) to one of two parallel groups - clinical and immunological versus clinical, immunological plus virologic (VL) monitoring for treatment failure with a 1:1 allocation ratio. The allocation sequence was concealed from study staff enrolling participants to prevent selection bias. Study staff involved in the clinical care were aware of a participant’s randomly allocated group due to the nature of study intervention (i.e. monitoring treatment effectiveness) but participants were kept blinded to their group allocation to prevent the likelihood of behavior modification (e.g., adherence) due to knowledge of group assignment. An independent data safety monitoring committee reviewed unblinded data for patient safety; no interim analyses for efficacy or futility were performed.
Eligibility/exclusion criteria
Eligible participants were HIV-infected children aged 1–12 years who (1) had a duration of at least 12 months on a first-line ART therapy and (2) were being monitored under a clinical and immunologic protocol to inform ART regimen change decisions prior to study enrollment. Exclusion was based on the use of second-line ART or PI-based regimen as first-line ART treatment, met immunologic criteria for second-line ART, active TB treatment, liver function tests (AST/ALT) > Grade 3* (5.1–10 times ULN or greater), and creatinine > Grade 3* (1.9–3.4 times ULN or greater) per DAIDS table for grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, Dated December 2004, Clarification August, 2009.
Study setting
The study took place at two HIV care centers - Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration/MTCT-Plus program and Nsambya Home Care (NHC) in Kampala, Uganda.
Anzeige
Study intervention
We enrolled 142 ART-experienced HIV-infected children aged 1–12 years, from an existing treatment program that used clinical and immunologic criteria to monitor response to ART in Kampala, Uganda into the study. The 71 children randomly assigned to each study arm underwent laboratory and clinical evaluations every 12 weeks during the 48 weeks follow-up period. Plasma HIV-1 RNA levels were measured at the MU-JHU Core laboratory with the use of the standard Roche Amplicor v1.5 test kit for the children in the clinical, immunologic & virologic arm.
At screening, viral load was assessed but clinicians were blinded prior to randomization. Information on baseline characteristics of the children including; type of ART, prior PMTCT Nevirapine (NVP) exposure, length on ART, clinical and immunological status, and demography were collected. At enrollment and during scheduled follow up visits; medical history, physical examination and information on child’s growth i.e. weight and height, was also collected on standardized study source forms.
Adherence monitoring during study follow up was done using self-report by the caretaker and child where applicable, pill counts at the scheduled visits and cross-checked with pharmacy records. For participants who had adherence challenges, unannounced pill counts were conducted during home visits.
The children remained on their first-line antiretroviral regimen until they were determined to have treatment failure. Since drug resistance testing was not done in real time, the decision to switch was made based on the assignment of monitoring arm. For Arm 1 this was based on; inadequate weight gain and or increasing WHO clinical staging (new or recurrent WHO clinical stage 3 or 4 events), CD4 values falling to < 200 cells/mm3 or CD4 percent < 10% for a child aged between 2 and 5 years of age, CD4 count of <100cell/mm3 for a child aged 5 years and above. For Arm 2 this was based on; confirmed viral load > 1000 HIV RNA copies/ml; as well as clinical and immunologic criteria described above. Having 2 confirmed viral loads > 1000 HIV RNA copies/ml at least 2 weeks apart confirmed a virologic endpoint in the study. Clinicians continued participants on first line regimen if viral load is < 5000 HIV RNA copies/ml as per the 2010 WHO guidelines.
Statistical analysis
The distribution of study participant characteristics in the overall study sample and differences between study arms were examined to validate study randomization procedures respectively.
All data analyses were conducted based on the intent-to-treat protocol. Mixed-effects logistic regression models were used to compare the odds (prevalence) of viral suppression between the two study arms over time. Each child was modeled as a random effect nested within treatment group. Time was modeled as a categorical variable.
Changes in the odds (prevalence) of viral suppression by study arm assignment were examined by testing the significance of the study arm x week interaction term with and without adjustment for potential confounders. In the absence of statistically significant interactions (at a Type I error rate of 0.05), independent study arm, week and other child characteristic effects were examined and reported. A six-step directed acyclic graph (DAG) approach [29] was used to inform final model covariate selection to reduce the potential for and degree of bias (i.e. confounding and incorrect adjustments for mediators of intervention effects on viral suppression).
Similar procedures described above were used to compare the odds of switching a child to second- line ART regimens between the two study arms and identify correlates of ART change decisions. Missing values in predictor variables were imputed using an R package called MICE 2.22 [30]. MICE function utilizes an approach of chained equations to impute incomplete multivariate data. Final statistical model results were generated using SAS 9.4 (SAS Institute Inc., Cary, North Carolina) with the level of significance set at the 0.05 level.
Results
Baseline and follow-up summary characteristics
Overall, 142 children were enrolled in the study and were evenly randomized to either the clinical + immunologic (control) or clinical + immunologic + virologic (intervention) monitoring study arm. The distribution of baseline characteristics did not differ by study arm (Table 1). Descriptive statistics by study arm for viral suppression (defined by < 1000 copies/ml), time-independent, and time dependent variables (ARV change, absolute CD4, CD4%) at baseline, 12, 24, 36 and 48 weeks are also summarized in Table 1.
Table 1
Baseline characteristics of study participants (HIV-infected children) by randomized study arm assignment (N = 142)
Characteristic
Overall
Clinical & Immunologic(N = 71)
Clinical, Immunologic & Virologic (N = 71)
P value
Study Site: n (%)
Mulago
70 (49)
35 (49)
35 (49)
1.000a
Nsambya
72 (51)
36 (51)
36 (51)
Age in years: Median (IQR)
6 (5, 9)
6 (5, 8)
7 (5, 9)
0.269b
Sex: n (%)
0.865a
Female
61 (43)
31 (43)
30 (42)
Male
81 (57)
40 (56)
41 (58)
WHO Stage: n (%)
0.947c
1
22 (15)
12 (17)
10 (14)
2
57 (40)
29 (41)
28 (39)
3
54 (38)
26 (37)
28 (39)
4
9 (6)
4 (6)
5 (7)
NVP Exposure: n (%)
0.938c
Yes
53 (37)
27 (38)
26 (37)
No
76 (54)
37 (52)
39 (55)
Unknown
13 (9)
7 (10)
6 (8)
In utero ART: n (%)
0.960c
Yes
43 (30)
21 (30)
22 (31)
No
82 (58)
41 (58)
41 (58)
Unknown
17 (12)
9 (12)
8 (11)
HIV RNA copies/ml: n (%)
0.722a
≤ 1000
94 (66)
46 (65)
48 (68)
> 1000
48 (34)
25 (35)
23 (32)
HIV RNA copies/ml: n (%)
1.000 a
≤ 400
92 (65)
46 (65)
46 (65)
> 400
50 (35)
25 (35)
25 (35)
ART Duration in years: Median (IQR)
4 (2, 5)
3 (2, 4)
4 (2, 5)
0.225b
CD cell count (%):
Median (IQR)
32 (26,38)
33 (26, 38)
32 (27, 38)
0.931 b
Absolute CD4 cell count:
Median (IQR)
1071
(759, 1416)
1097
(776, 1537)
1032
(721, 1326)
0.501 b
BMI-for-age Z:
Median (IQR)
−0.26
(−0.92, 0.36)
−0.21
(−1.06, 0.43)
−0.28
(−0.88, 0.29)
0.875 b
Weight-for-age Z score: Median (IQR)
− 0.97
(− 1.54, − 0.25)
− 0.97
(− 1.37, − 0.33)
− 0.99
(− 1.63, − 0.15)
0.933 b
Height-for-age Z score:
Median (IQR)
−1.07
(− 1.92, − 0.34)
−1.10
(− 1.76, − 0.28)
−1.03
(− 1.93, − 0.41)
0.979 b
Missing: %CD4–15; Abs CD4–2
aChi-square test; bWilcoxon Two-Sample test; cFishers-Exact test
Of the 142 participants, 129 (91%) and 134 (94%) completed the 24- and 48-week assessments, respectively. The intervention study arm (clinical + immunologic + virologic monitoring) had additional assessments at 12 (response rate: 100%) and 36 (response rate: 96%) weeks; however, overall, there were no differences in response rate by study arm (p = 0.98).
Viral suppression
Overall, 92 (64%), 86 (67%) and 93 (69%) children had viral suppression at baseline, 24 and 48 weeks respectively. The prevalence of viral suppression did not differ by study arm during follow-up (study arm x week interaction term: p = 0.63). Overall, the odds of viral suppression were not different between study arms (Clinical, Immunologic & Virologic) vs Clinical & Immunologic (Fig. 1): [aOR]: 1.07; 95%CI: 0.53, 2.17, p = 0.57) and did not change over time [Fig. 2] (aOR: 0 vs 24 week: 1.15; 95% CI: 0.91, 1.46, p = 0.24 and 0 vs 48 weeks: 1.26; 95%CI: 0.92, 1.74, p = 0.15). Having no history of NVP exposure (aOR: 2.75; 95%CI: 1.19, 6.37), higher baseline CD4% cell count (Fig. 3) (aOR: 1.09; 95%CI: 1.04, 1.15) or absolute (log transformed) CD4 count (aOR: 2.75; 95%CI: 1.17, 15.18) were associated with higher odds of viral suppression over time. Longer durations on ART was associated with lower odds of viral suppression (aOR: 0.67; 95%CI: 0.49, 0.91). Although, the prevalence of viral suppression was higher among children who had had a drug switch in their ARV regimen (80%) versus those that did not (66%) at 24 weeks (Table 2), overall, a change in ARV regimen (defined as 3 drug change to change to second line) did not predict viral suppression over time (aOR: 0.85; 95% CI: 0.27, 2.73). Study site, age, sex, baseline WHO stage, in-utero ART exposure, age-adjusted BMI, weight and height were not associated with viral suppression over time (Table 2).
Fig. 1
Estimated prevalence of viral load suppression (< 400 copies/ml) by study arm during a 48-week follow-up
Fig. 2
Mean Log (HIV RNA copies/ml) by study arm during a 48-week follow-up. Undetected virus levels rounded off to 1 copy/ml (log (1) =0). Overall and within-study arm median HIV RNA copies/ml was zero
Fig. 3
Mean CD4 cell % by study arm during a 48-week follow-up
Table 2
Prevalence of viral suppression, crude and adjusted odds ratios (with 95%CI) summarizing the relationship between selected risk factors and viral suppression during a 48 week follow-up period among HIV-infected children in Uganda (N = 142)
Characteristic
Viral suppression by week
Crude Odds Ratio
Adjusted Odds Ratio
Baseline
n (%)
24 Weeks
n (%)
48 Weeks
n (%)
OR (95% CI)
aOR (95% CI)
Monitoring arm
Immunologic
46 (65)
43 (68)
46 (70)
Ref
Ref a
Immunologic & Virologic
46 (65)
43 (65)
47 (69)
0.88 (0.46; 1.69)
1.06 (0.47; 2.42)
ARV Change∫
No
78 (66)
77 (69)
Ref
Ref
Yes
8 (80)
16 (70)
1.52 (0.59; 3.89)
0.85 (0.27; 2.73)
Study Site
Mulago
43 (61)
38 (59)
43 (63)
Ref
Ref b
Nsambya
49 (68)
48 (74)
50 (76)
1.56 (0.82; 2.99)
0.70 (0.25; 1.96)
Sex
Female
39 (64)
34 (63)
41 (69)
Ref
Ref c
Male
53 (65)
52 (69)
52 (69)
1.12 (0.58; 2.15)
1.01 (0.45; 2.26)
WHO Stage
1
16 (73)
12 (63)
14 (66)
Ref
Ref d
2
38 (67)
40 (78)
40 (74)
1.14 (0.42; 3.09)
0.63 (0.17; 2.26)
3
33 (61)
31 (61)
33 (66)
0.74 (0.28; 1.98)
0.49 (0.14; 1.66)
4
5 (56)
3 (38)
6 (67)
0.55 (0.13; 2.32)
0.28 (0.05; 1.63)
NVP Exposure
Yes
27 (51)
28 (55)
28 (56)
Ref
Ref e
No
56 (74)
47 (72)
55 (77)
2.61 (1.31; 5.21)**
2.75 (1.19; 6.37)**
Unknown
9 (69)
11 (85)
10 (77)
2.92 (0.83; 10.32)
In utero ART
Yes
27 (63)
25 (60)
24 (57)
Ref
Ref f
No
51 (62)
47 (65)
54 (72)
1.37 (0.67; 2.77)
1.20 (0.53; 2.74)
Unknown
14 (82)
24 (93)
15 (88)
5.10 (1.26; 20.61)*
–
Age (years)
1.01 (0.90; 1.16)
1.19 (0.97; 1.48)g
ART duration (years)
0.70 (0.56; 0.88)**
0.67 (0.49; 0.91)h*
CD%/cell count
1.03 (0.99; 1.07)
1.09 (1.04; 1.15)i*
Log (Absolute CD4)
2.82 (1.39, 5.69)**
2.75 (1.17; 15.18)i*
BMI-for-age Z:
0.79 (0.61; 1.01)
0.85 (0.62; 1.15)j
Weight-for-age Z:
0.96 (0.73; 1.28)
1.11 (0.75; 1.64)j
Height-for-age Z:
1.21 (0.91; 1.61)
1.33 (0.91; 1.93)j
*p < 0.05; **p < 0.01
aAdjusted for week, location, sex, age, NVP exposure, In-utero ART, ART duration, Absolute CD4
bAdjusted for study arm, week, sex, age, NVP exposure, In-utero ART, ART duration, Absolute CD4
cAdjusted for study arm, week, Absolute CD4
dAdjusted for study arm, week, location, sex, and in-utero ART
eAdjusted for study arm, week, location, WHO stage, in-utero ART, ART duration and BMI-for-age Z
fAdjusted for study arm, week, and location
gAdjusted for study arm, week, location, sex, NVP exposure, In-utero ART, and BMI-for-age Z
hAdjusted for study arm, week, location, WHO stage, NVP exposure, In-utero ART, and BMI-for-age Z
iAdjusted for study arm, week, location, sex, NVP exposure, In-utero ART, and BMI-for-age Z
jAdjusted for study arm, week, location, sex, NVP exposure, In-utero ART, ART duration and Absolute CD4
∫ARV Change – Time dependent (varying) variable (adjusted for study arm, week, location, NVP exposure, ART duration and baseline absolute CD4 count)
×
×
×
ARV changes
The prevalence of ARV switching during follow-up did not differ by study arm [Fig. 4] (study arm x week interaction term = 0.39). Overall, the odds of ARV changes did not differ between study arms ([aOR]: 1.58; 95%CI: 0.62; 4.00) but increased over time; the odds of switching a child’s ARV regimen were 5.37 (aOR: 95%CI: 3.02, 7.97) and 24.10 (aOR: 95%CI: 9.14, 63.56) times higher at 24 and 48 weeks, respectively adjusted for study arm assignment and suspected confounders i.e. (log (HIV RNA copies/ml), study arm, week, NVP exposure, ART duration, and location).
Fig. 4
Estimated prevalence of ARV change by study arm during a 48-week follow-up, Phase I
×
The prevalence of switching to second-line ARV regimens increased over time: 8 and 17% at 24 and 48 weeks, respectively. The overall odds of switching a child’s ARV did not differ by NVP exposure, ART duration and study site (Table 3). Changes in viral load and CD4 cell count did not predict switches in ARV regimens either (Table 3).
Table 3
Prevalence of ARV change, crude and adjusted odds ratios (with 95%CI) summarizing the relationship between selected risk factors and ARV change during a 48 week follow-up period among HIV-infected children in Uganda (N = 142)
Characteristic
ARV changed by week
Crude Odds Ratio
Adjusted Odds Ratio
12
n (%)
24
n (%)
36
n (%)
48
n (%)
OR (95% CI)
OR (95% CI)
Overall
2 (1)
10 (8)
12 (9)
23 (17)
Monitoring arm
Immunologic
–
3 (5)
–
9 (14)
Ref
Ref
Virologic
2 (3)
7 (11)
12 (18)
14 (21)
1.52 (0.59; 3.89)
1.58 (0.62; 4.00) a
∫log (HIV RNA copies/ml)
0.97 (0.90; 1.05)
1.02 (0.92; 1.12)a
∫Log (ABS CD4)
0.91 (0.44; 1.86)
0.77 (0.29; 2.00)b
∫CD4%
0.99 (0.96; 1.04)
0.97 (0.92; 1.04)b
Week
Baseline
Ref
Ref*
24
1.91 (1.19; 3.07)
5.37 (3.02; 7.97) a
48
3.65 (1.40; 9.45)
24.10 (9.14; 63.56) a
*p < 0.05; **p < 0.01
Participants who had an ARV change are counted in the prevalence estimate at subsequent follow-up
a Covariates in the final adjusted model: log (HIV RNA copies/ml), study arm, week, NVP exposure, ART duration, and location
b Covariates in the final adjusted model: study arm, week, NVP exposure, ART duration, and location
∫Time dependent variable
Discussion
Recommendation for ART monitoring has gradually changed over time. Initially, patients’ CD4 T Cells were monitored every 6 months and viral load testing was only done when possible. Currently, WHO recommends viral load as the preferred monitoring approach to diagnose and confirm treatment failure, with viral load testing being conducted at 6 and 12 months after ART initiation and every 12 months thereafter [31]. Viral load monitoring in children is required every 6 months.
In this analysis of Ugandan children and adolescents, our findings show that the addition of periodic (annual) virologic testing to standard of care (clinical and immunological monitoring) among treatment-experienced HIV infected children was not associated with a higher prevalence of viral suppression. The results do however support the need for virologic monitoring as a better strategy for early detection of virologic failure especially with increased duration of ART exposure, since immunologic monitoring is a poor predictor of treatment failure. Our findings are in agreement with previous Sub-Saharan Africa studies which have shown that clinical and immunologic monitoring is not sufficient to detect virologic failure in a timely manner [14, 16, 32], which further supports the need for viral load testing as a strategy to monitor response to treatment in children. This is similar to findings from a study done in Uganda and Zimbabwe, the ARROW TRIAL which highlighted the importance of confirming virological failure before switching to second-line ART, since some children with detectable low-level viraemia spontaneously re-suppressed [33].
Additionally, our study showed no evidence to suggest virologic testing results in better treatment decisions (i.e. switching to second-line ARVs) linked to better clinical outcomes (i.e. viral suppression). Although the odds of switching a child’s ARV regimen were not different between study arms, the odds of switching to second-line regimens increased over time but were not predicted by a child’s treatment exposure history or immunological parameters. Our study highlights the need to operationalize monitoring results into algorithms to inform ARV change decisions since there appears to be a disconnect between monitoring results and actual decisions to switch ARVs.
Anzeige
Independent of study arm assignment, having no history of NVP exposure, higher baseline CD4% cell count or absolute CD4 count were associated with higher odds of viral suppression over time while longer duration on ART was associated with lower odds of viral suppression. A similar study done in Tanzania in perinatally HIV infected children [34] also showed that longer duration on ART was associated with poor virologic outcomes due to selection of resistance mutations making their virus more difficult to suppress. This NNRTI resistance pattern is very common in many countries, Uganda inclusive where non-nucleoside reverse transcriptase inhibitors (NNRTIs) of which nevirapine is part were used as part of a first-line ART regimen. In addition, children in this study were exposed to single dose nevirapine for PMTCT and their mothers also received nevirapine which could have lowered their odds of virologic suppression, a trend consistent with previous studies [35‐38]; this may explain our null intervention effect [39, 40].
In contrast to previous studies [41, 42], our study findings suggest that the addition of periodic (annual) virologic testing did not change the prevalence of ART switching decisions between the two study arms, although the viral load monitoring was able to identify virological failure sooner than the ones who were monitored clinically and immunologically. The delay in switching could have been due to lack of clear guidelines at the time on when to switch, limited ART options and lack of confidence on the part of the health care providers to switch ART. The number of children switched to second-line ART was small in this study and if only immunological monitoring was used to determine when to switch to second-line ART, the percentage of children switched to second-line ART would have been much less. Viral load monitoring should be utilized to identify treatment failure early and thereafter make the necessary changes (28) which would reduce accumulation of drug resistance mutations and limited treatment options for second-line ART (29).
The strengths of this study include the longitudinal laboratory and clinical monitoring as well as the high rates of follow up with minimal losses to follow up during the 48-week period. The children in the two arms were comparable in terms of baseline characteristics and virologic suppression at baseline.
The limitations of this study include the partial blinding, the short follow up period of 48 weeks and a relatively small sample size of perinatally HIV infected children and adolescents, which may not be generalizable to all ART experienced children. Both the study staff enrolling participants and the participants were blinded to the assignment however, the clinical care staff were not. This could have influenced the behaviour of study staff towards participants. Longer duration of follow up and a larger sample size would confirm the findings of this study. However, the current guidelines and practice recommend that all children on ART should have routine VL monitoring.
Anzeige
Conclusion
The results of this study confirm that virologic monitoring is a superior strategy for detecting early HIV treatment failure especially with the increasing duration of ART exposure among adolescents and lend credence and support to the current WHO guidelines on ART monitoring. The issue of availability and cost of viral load testing still remains a challenge, especially in high burden countries in Sub-Saharan Africa. Therefore, studies to evaluate the affordability and accessibility of these services in resource limited settings will further inform the current WHO recommendations. In addition, there is need to operationalize monitoring results into algorithms to inform ART change decisions since there appears to be a disconnect between monitoring results and actual decisions to switch ART by health workers after ART treatment failure is identified.
Acknowledgements
We thank the children, their families, and their caregivers who agreed to participate In the TIBOTEC and Optimal Care Study. We would like to acknowledge the staff based at Nsambya Home Care (NHC) and Makerere University-Johns Hopkins University (MU-JHU) under the leadership of Dr. Linda Barlow-Mosha (Tibotec REACH Initiatives recipient and Thrasher Research Fund # 9415) without whose dedication this study could not have been done. We also acknowledge all the support offered by MUJHU regulatory team while ensuring quality of the study findings. We sincerely appreciate the Tibotec REACH Initiatives and Thrasher award foundation for funding this study. The content is solely the responsibility of the authors and does not necessarily represent the views of the Tibotec REACH Initiatives and Thrasher award.
Declarations
Ethics approval and consent to participate
The study was approved by the School of Medicine Research Ethics Committee (SOMREC) [REC REF 2009–173] and Uganda National Council for Science and Technology [UNCST Ref #HS 719]. All caretakers provided written informed consent, and children above 8 years provided assent as required by Uganda regulatory guidelines.
Consent for publication
All caretakers provided written informed consent, and children above 8 years provided assent as required by Uganda regulatory guidelines. Within the consent form that was read and signed by the caretakers, there was a section about results from the study being published while maintaining participant confidentiality.
Anzeige
Competing interests
The authors declare that they have no competing interests and have received no payment in preparation of this manuscript.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load
verfasst von
Phionah Kibalama Ssemambo Mary Gorrethy Nalubega-Mboowa Arthur Owora Robert Serunjogi Susan Kironde Sarah Nakabuye Francis Ssozi Maria Nannyonga Philippa Musoke Linda Barlow-Mosha
Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.
Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.
Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.
Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.
Update Pädiatrie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
